Mr. Ezickson currently serves as the Founding CEO of Sporos Bioventures, where he brings extensive biopharmaceutical operational, strategic and capital formation expertise. Prior to Sporos, he most recently served as the Chief Operating Officer and head of corporate development at Scholar Rock Holding Corporation, a clinical stage biotechnology company focused on novel oncology and rare disease treatments. At Scholar Rock, he directed corporate development, operations and strategy, and played a significant role in corporate finance, leading the company’s initial public offering. Prior to joining Scholar Rock, he served as Executive Vice President and Chief Operating Officer of Aveo Pharmaceuticals where he built and oversaw corporate development, commercial operations, technical operations, medical affairs, program management and legal functions and led capital raising and licensing efforts with multinational pharmaceutical companies.
Prior to Aveo, Mr. Ezickson was at Biogen in roles that included President of Biogen Canada, Program Executive and Associate General Counsel. He currently serves on the Boards of Directors of a number of public and private biotechnology firms including Sporos Bioventures, Marinus Pharmaceuticals, Ziopharm Oncology, Carmine Therapeutics, Tvardi Therapeutics and Asylia Therapeutics. Mr. Ezickson holds a Bachelor of Arts degree in political science from Yale University and a Juris Doctorate from the Columbia University School of Law.